Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
McGill University Health Center |
---|---|
Information provided by: | McGill University Health Center |
ClinicalTrials.gov Identifier: | NCT00498121 |
Our aim in this study is to investigate the potential role of serum ProCT as an early diagnostic marker and later prognostic indicator for VAP.
Condition | Intervention |
---|---|
Ventilator Associated Pneumonia |
Device: PROCALCITONIN LEVEL |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | The Diagnostic and Prognostic Utility of Procalcitonin (ProCT) for Ventilator-Associated Pneumonia (VAP) |
Estimated Enrollment: | 50 |
Study Start Date: | July 2007 |
Estimated Study Completion Date: | July 2008 |
Groups/Cohorts | Assigned Interventions |
---|---|
VAP patient |
Device: PROCALCITONIN LEVEL
measuring PROCALCITONIN LEVEL
|
Ventilator-associated pneumonia (VAP), a bacterial infection that develops after 48 hours or more of intubation, is associated with high morbidity and mortality. Rapid identification of VAP is required to improve survival and to reduce avoidable treatment-associated side effects. Procalcitonin (ProCT), a blood test, is a reasonably specific marker of bacterial infection and its level increases early in sepsis. In this study, a ProCT serum level will be measured in 50 patients with clinically suspected VAP. We aim to show that the ProCT level will be high early in VAP and will stay high in patients with poor prognosis. This will help to address the potential role of ProCT as part of early diagnosis and management of VAP.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Patients who are intubated or more than 48 hours
Inclusion Criteria:
In the preceding 24 h, the appearance of a new opacity or opacities on chest X-ray when compared to previous, and two of the following:
Exclusion Criteria:
Contact: Salman A Qureshi, MD,FRCPSC | (514) 9341934 ext 44626 | salman.qureshi@mcgill.ca |
Contact: Mohammed B Alsaiari, MD,FRCPSC | (514) 4027747 ext - | mbasi100@hotmail.com |
Canada, Quebec | |
McGill University Health Centre | Recruiting |
Montreal, Quebec, Canada, H3A 1A1 | |
Contact: Mohammed B Alsaiari, MD,FRCPSC (514) 4027747 ext - mbasi100@hotmail.com | |
Contact: Mohammed B Alsaiari, MD,FRCPSC (514) 4027747 ext - mbasi100@hotmail.com | |
Principal Investigator: Mohammed B Alsaiari, MD,FRCPSC |
Principal Investigator: | Salman A Qureshi, MD,FRCPSC | McGill University Health Center |
Responsible Party: | McGill University Health Center ( McGill University Health Center ) |
Study ID Numbers: | mbasi100 |
Study First Received: | July 6, 2007 |
Last Updated: | March 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00498121 History of Changes |
Health Authority: | Canada: Canadian Institutes of Health Research; Canada: Ethics Review Committee; Canada: Health Canada |
Ventilator associated pneumonia. Procalcitonin. |
Respiratory Tract Infections Respiratory Tract Diseases Lung Diseases |
Pneumonia, Ventilator-Associated Cross Infection Pneumonia |
Respiratory Tract Infections Respiratory Tract Diseases Lung Diseases Infection |
Pneumonia, Ventilator-Associated Cross Infection Pneumonia |